E³ - The Beauty of Basic Knowledge: Hybrid Imaging
E³ 24A - Hybrid imaging in oncology (part 1): where is it standard-of-care?
Lectures
1
Chairperson's introduction
05:00Clemens C. Cyran, München / DE
2
Hybrid imaging in haematological malignancies
15:00Marius E. Mayerhöfer, Vienna / AT
3
Head and neck tumours: hybrid imaging for guiding therapy
15:00Andrew Scarsbrook, Leeds / UK
4
PET/CT for lung cancer therapy management
15:00Helmut Prosch, Vienna / AT
5
Panel discussion: Hybrid imaging as standard-of-care: accessibility guaranteed?
10:00Panel discussion: Hybrid imaging as standard-of-care: accessibility guaranteed?
5 min
Chairperson's introduction
Clemens C. Cyran, München / Germany
15 min
Hybrid imaging in haematological malignancies
Marius E. Mayerhöfer, Vienna / Austria
Learning Objectives
1. To understand the role of imaging in haematological malignancies therapy guidance.
2. To define the advantages of hybrid imaging compared to conventional imaging.
3. To get acquainted with radiotracers beyond FDG.
2. To define the advantages of hybrid imaging compared to conventional imaging.
3. To get acquainted with radiotracers beyond FDG.
15 min
Head and neck tumours: hybrid imaging for guiding therapy
Andrew Scarsbrook, Leeds / United Kingdom
Learning Objectives
1. To identify key indications for hybrid imaging in head and neck cancer patients.
2. To list different semi-quantitative PET-based criteria which can be used for assessing treatment response.
3. To become familiar with methods for dealing with indeterminate findings that might cause interpretative difficulties.
2. To list different semi-quantitative PET-based criteria which can be used for assessing treatment response.
3. To become familiar with methods for dealing with indeterminate findings that might cause interpretative difficulties.
15 min
PET/CT for lung cancer therapy management
Helmut Prosch, Vienna / Austria
Learning Objectives
1. To become familiar with the strengths and limitations of FDG-PET-CT in lung cancer staging.
2. To understand the role of PET-CT in evaluating treatment response in lung cancer patients.
3. To develop a comprehensive understanding of the latest tracers utilised in lung cancer imaging.
2. To understand the role of PET-CT in evaluating treatment response in lung cancer patients.
3. To develop a comprehensive understanding of the latest tracers utilised in lung cancer imaging.
10 min
Panel discussion: Hybrid imaging as standard-of-care: accessibility guaranteed?